Disease · HP_0000713
Agitation
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Agitation. Diseases, record HP_0000713. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000713
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Agitation
- Open Targets ID
- HP_0000713
- Other names
- Psychomotor agitation
- Highest stage of its drugs
- Approval, for 7 of its 57 drugs, from DailyMed, FDA, PMDA and TTD
Source Open Targets
Drugs57
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LOXAPINE | CHEMBL831 | Small molecule | Approval | DailyMed | 10 | 8 | 8 | Drugs and targets |
| OLANZAPINE | CHEMBL715 | Small molecule | Approval | DailyMed and PMDA | 30 | 7 | 7 | Drugs and targets |
| ARIPIPRAZOLE | CHEMBL1112 | Small molecule | Approval | DailyMed and FDA | 12 | 2 | 2 | Drugs and targets |
| DIAZEPAM | CHEMBL12 | Small molecule | Approval | DailyMed | 68 | 0 | 0 | Drugs and targets |
| ZIPRASIDONE HYDROCHLORIDE | CHEMBL1375743 | Small molecule | Approval | DailyMed | 2 | 0 | 0 | Drugs and targets |
| OXAZEPAM | CHEMBL568 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| PROMAZINE | CHEMBL564 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| DEXMEDETOMIDINE | CHEMBL778 | Small molecule | Phase 3 | ClinicalTrials.gov | 21 | 21 | 19 | Drugs and targets |
| HALOPERIDOL | CHEMBL54 | Small molecule | Phase 3 | ClinicalTrials.gov | 13 | 13 | 13 | Drugs and targets |
| MIDAZOLAM | CHEMBL655 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 10 | Drugs and targets |
1 to 10 of 57
See all 57 drugsTargets69
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| HTR2A | 5-hydroxytryptamine receptor 2A | 15 | Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2a (5-HT2a) receptor inverse agonist | Approval | https://conductscience.org/library/genes/3356 | Drugs and targets |
| DRD2 | D(2) dopamine receptor | 14 | D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor partial agonist | Approval | https://conductscience.org/library/genes/1813 | Drugs and targets |
| HTR2C | 5-hydroxytryptamine receptor 2C | 9 | Serotonin 2c (5-HT2c) receptor antagonist | Approval | https://conductscience.org/library/genes/3358 | Drugs and targets |
| GABRA1 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator | Approval | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator | Approval | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator | Approval | https://conductscience.org/library/genes/2556 | Drugs and targets |
| GABRA4 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator | Approval | https://conductscience.org/library/genes/2557 | Drugs and targets |
| GABRA5 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator | Approval | https://conductscience.org/library/genes/2558 | Drugs and targets |
| GABRA6 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator | Approval | https://conductscience.org/library/genes/2559 | Drugs and targets |
| GABRB1 | GABA-A receptor; anion channel | 5 | GABA-A receptor; anion channel positive allosteric modulator | Approval | https://conductscience.org/library/genes/2560 | Drugs and targets |
1 to 10 of 69
See all 69 targetsTrials93
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 6 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02446132 | Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type | Phase 3 | 1,197 | 2025-10-15 | Agitation in Patients With Dementia of the Alzheimer's Type | DEUDEXTROMETHORPHAN, QUINIDINE SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT02442778 | Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type | Phase 3 | 522 | 2022-09-09 | Agitation in Participants With Dementia of the Alzheimer's Type | DEUDEXTROMETHORPHAN, QUINIDINE SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT01862640 | A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation | Phase 3 | 433 | 2020-06-16 | Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases | BREXPIPRAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT03620981 | Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type | Phase 2/3 | 410 | 2024-11-14 | Agitation Associated With Dementia of the Alzheimer's Type | BREXPIPRAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT02442765 | Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type | Phase 3 | 387 | 2023-02-13 | Agitation in Patients With Dementia of the Alzheimer's Type | DEUDEXTROMETHORPHAN HYDROBROMIDE, QUINIDINE SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT04276883 | Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder | Phase 3 | 380 | 2023-09-11 | Agitation Associated With Bipolar Disorder, Agitation,Psychomotor, Bipolar Disorder | DEXMEDETOMIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT00723606 | A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation | Phase 3 | 376 | 2010-08-25 | Schizophrenia | HALOPERIDOL, ZIPRASIDONE | Its record names the disease | ClinicalTrials.gov |
| NCT00857649 | Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease | Phase 3 | 369 | 2012-01-09 | Alzheimer's Disease | MEMANTINE | Its record names the disease | ClinicalTrials.gov |
| NCT03226522 | Addressing Dementia Via Agitation-Centered Evaluation | Phase 2/3 | 366 | 2023-09-13 | Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor | BUPROPION | Its record names the disease | ClinicalTrials.gov |
| NCT01735630 | Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease | Phase 2 | 350 | 2016-08-15 | Alzheimer's Disease | SCYLLITOL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 93
See all 93 trialsComparisons in its trials25
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ziprasidone vs Haloperidol: serious adverse events | 0 of 189 | 0 of 187 | 376 | NCT00723606 | Trial comparisons |
| Memantine vs Placebo: serious adverse events | 18 of 182 | 11 of 187 | 369 | NCT00857649 | Trial comparisons |
| ELND005 vs Placebo: serious adverse events | 17 of 175 | 5 of 175 | 350 | NCT01735630 | Trial comparisons |
| Brexpiprazole (Flexible Dose Range 0.5 to 2 mg/Day) vs Placebo (Flexible Dose Range 0.5 to 2 mg/Day): deaths from any cause | 0 of 132 | 1 of 137 | 269 | NCT01922258 | Trial comparisons |
| Brexpiprazole (Flexible Dose Range 0.5 to 2 mg/Day) vs Placebo (Flexible Dose Range 0.5 to 2 mg/Day): serious adverse events | 7 of 132 | 6 of 137 | 269 | NCT01922258 | Trial comparisons |
| Prior Brexpiprazole vs Prior Placebo: deaths from any cause | 0 of 163 | 0 of 96 | 259 | NCT03594123 | Trial comparisons |
| Prior Brexpiprazole vs Prior Placebo: serious adverse events | 6 of 163 | 0 of 96 | 259 | NCT03594123 | Trial comparisons |
| All AVP-786 vs All Placebo: deaths from any cause | 0 of 115 | 0 of 83 | 198 | NCT03095066 | Trial comparisons |
| All AVP-786 vs All Placebo: serious adverse events | 3 of 115 | 0 of 83 | 198 | NCT03095066 | Trial comparisons |
| Citalopram and Psychosocial Intervention vs Placebo and Psychosocial Intervention: serious adverse events | 8 of 94 | 7 of 92 | 186 | NCT00898807 | Trial comparisons |
1 to 10 of 25
See all 25 comparisons in its trialsPapers from its trials94
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0000713
GET https://conductscience.org/api/diseases/v1/HP_0000713/drugs?page=2